Trial
NCT00023881
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Leukemia
Intervention
bortezomib
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-14